TCR2 Therapeutics Inc.
TCRRDelisted Jun 1, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750019
TCR2 Therapeutics Inc. was delisted on Jun 1, 2023; its insiders filed their last Form 4 on Feb 14, 2024; 59 institutions reported holding it in 13F filings for Q1 2023, worth $31.5M in total; no superinvestor held it.
Q4 2021 vs. Q3 2021
How the institutions holding TCR2 Therapeutics Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 117 | 3 | 122 | +8 |
| Shares | 31.8M | 546.9K | 29.2M | −2.10M (−6.7%) |
| Value | $271.1M | $4.65M | $136.0M | −$130.4M (−49.0%) |
3 institutions that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (40)
Institutions that held TCR2 Therapeutics Inc. at the end of Q4 2021 but not at the end of Q3 2021.
Sold out (32)
Institutions that held TCR2 Therapeutics Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
Not filed for Q4 2021 yet (3)
Institutions that held TCR2 Therapeutics Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Marshall Wace North America L.P. | 543,582 | $4.63M |
| First Mercantile Trust Co | 3,292 | $28.0K |
| Berman Capital Advisors, LLC | 70 | $0 |